Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.62 |
| ▸ | MCHR1 | Q99705 | 15/20 | 0.58 |
| ▸ | HTR2C | P28335 | 1/20 | 0.58 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.52 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4028849 | 0.88 | MCHR1 (0.54) | MAPK1MCHR1HTR2CLTB4RPRSS1 | |
| SCHEMBL6811199 | 0.83 | MAPK1 (0.68) | MAPK1MCHR1PRSS1 | |
| SCHEMBL30969248 | 0.83 | MAPK1 (0.68) | MAPK1MCHR1PRSS1 | |
| SCHEMBL6174553 | 0.81 | MCHR1 (0.55) | MCHR1HTR2C | |
| SCHEMBL6941556 | 0.80 | MAPK1 (0.72) | MAPK1PRSS1 | |
| SCHEMBL9502719 | 0.80 | MAPK1 (0.72) | MAPK1PRSS1 | |
| SCHEMBL12970778 | 0.80 | MAPK1 (0.72) | MAPK1PRSS1 | |
| SCHEMBL4028851 | 0.79 | FDPS (0.58) | MAPK1 | |
| SCHEMBL4198415 | 0.79 | GAA (0.55) | MCHR1HTR2C | |
| SCHEMBL1545264 | 0.78 | MAPK1 (0.68) | MAPK1LTB4RPRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080108615-A1 | Imidazole-2-Carboxamide Derivatives as Raf Kinase Inhibitors | SMITHKLINE BEECHAM P.L.C | 2008-05-08 | — | — | US | claimed |
| EP-1397354-B1 | IMIDAZOLE-2-CARBOXAMIDE DERIVATIVES AS RAF KINASE INHIBITORS | SMITHKLINE BEECHAM PLC (GB) | 2005-10-26 | — | — | EP | claimed |
| US-20040063686-A1 | Carboxamide compounds and their use as antagonists of a human 11cby receptor | JOHNSON CHRISTOPHER NORBERT (GB) | 2004-04-01 | — | — | US | disclosed |
| EP-1305304-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS ANTAGONISTS OF A HUMAN 11CBY RECEPTOR | SMITHKLINE BEECHAM PLC (GB) | 2003-05-02 | — | — | EP | disclosed |
| WO-2002010146-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS ANTAGONISTS OF A HUMAN 11CBY RECEPTOR | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063686-A1 | Carboxamide compounds and their use as antagonists of a human 11cby receptor | CNR1, GPR3, CCKAR | MAPK1 1964/4885MCHR1 133/4885HTR2C 93/4885 |
| US-20080108615-A1 | Imidazole-2-Carboxamide Derivatives as Raf Kinase Inhibitors | BRAF, RAF1, ARAF | MAPK1 65/4885MCHR1 4682/4885HTR2C 2730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.